Joyce A. O’Shaughnessy, MD
Results from the phase III TAILORx study will enable physicians to reduce the toxicity of treatment for many patients with early stage breast cancer, according to Joyce A. O’Shaughnessy, MD.
Of 6711 evaluable women with an intermediate recurrence score of 11 to 25, investigators randomized 3399 to receive endocrine therapy alone and 3312 to receive endocrine therapy plus chemotherapy. Randomization was based on these stratification factors: menopausal status, planned chemotherapy, planned radiation, and recurrence score groups.
... to read the full story